Loading clinical trials...
Loading clinical trials...
The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytia...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
NCT07220109 · Respiratory Syncytial Virus Infections
NCT07092865 · Respiratory Syncytial Virus Infections
NCT07239583 · Respiratory Syncytial Virus Infection, Respiratory Syncytial Virus Infections
NCT04732871 · Respiratory Syncytial Virus Infections
NCT06534892 · Respiratory Syncytial Virus Infections
Investigational Site Number : 0360006
Blacktown, New South Wales
Investigational Site Number : 0360001
Botany, New South Wales
Investigational Site Number : 0360009
Brookvale, New South Wales
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions